Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2009
  • Online publication date: July 2016

Chapter 17 - Neuro-inflammation:

from Section 4: - Therapy


Aisen PS, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. J Am Med Assoc 2003; 289: 2819–26.
Alder J, et al. Interferon-gamma dose-dependently inhibits prostaglandin E2-mediated dendritic-cell-migration towards secondary lymphoid organ chemokines. Vaccine 2006; 24: 7087–94.
Balatoni B, et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull 2007; 74: 307–16.
Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 2006; 19: 341–9.
Bechtold DA, et al. Axonal protection achieved in a model of multiple sclerosis using lamotrigine. J Neurol 2006; 253:1542–51.
Bielekova B, et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000; 6: 1167–75.
Bielekova B, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 2004; 101: 8705–8.
Black JA, et al. Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Ann Neurol 2007; 62: 21–33.
Bredesen DE, et al. Cell death in the nervous system. Nature 2006; 443: 796–802.
Brendza RP, Holtzman DM. Amyloid-beta immunotherapies in mice and men. Alzheimer Dis Assoc Disord 2006; 20: 118–23.
Brocke S, et al. Antibodies to CD44 and integrin alpha4, but not l-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 1999; 96: 6896–901.
Buch T, Waisman A. Protection from autoimmunity by DNA vaccination against T-cell receptor. Meth Mol Med 2006; 127: 269–80.
Calabresi PA, et al. An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS. Neurology 2002; 58: 314–17.
Callahan MK, Ransohoff RM. Analysis of leukocyte extravasation across the blood–brain barrier: Conceptual and technical aspects. Curr Allergy Asthma Rep 2004; 4: 65–73.
Carri MT, et al. Targets in ALS: designing multidrug therapies. Trends Pharmacol Sci 2006; 27: 267–73.
Cavaletti G. Current status and future prospective of immunointervention in multiple sclerosis. Curr Med Chem 2006;13: 2329–43.
Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun Rev 2004; 3: 251–60.
Coles AJ, et al. Alemtuzumab vs. Interferon Beta-1a in early multiple sclerosis. N Engl J Med 2008; 359: 1786–801.
Confavreux C, Moreau T. Emerging treatments in multiple sclerosis: Azathioprine and mofetil. Mult Scler 1996; 1: 379–84.
Cosentino M, et al. Interferon-gamma and interferon-beta affect endogenous catecholamines in human peripheral blood mononuclear cells: Implications for multiple sclerosis. J Neuroimmunol 2005; 162: 112–21.
Creput C, et al. New therapeutic targets for antibodies and recombinant proteins in organ transplantation. Curr Opin Mol Ther 2007; 9: 153–9.
Cross AH, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180: 63–70.
Cysique LA, et al. Valproic acid is associated with cognitive decline in HIV-infected individuals: A clinical observational study. BMC Neurol 2006; 6: 42.
Defeudis FV. Bilobalide and neuroprotection. Pharmacol Res 2002; 46: 565–8.
Dou H, et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 2003; 23: 9162–70.
Dyke HJ, Montana JG. Update on the therapeutic potential of PDE4 inhibitors. Expert Opin Investig Drugs 2002; 11: 1–13.
Edling AE, et al. An organic CD4 inhibitor reduces the clinical and pathological symptoms of acute experimental allergic encephalomyelitis. J Autoimmun 2002; 18: 169–79.
Emerich DF, Thanos CG. Intracompartmental delivery of CNTF as therapy for Huntington’s disease and retinitis pigmentosa. Curr Gene Ther 2006; 6: 147–59.
Fernandez-Martin A, et al. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease. Ann NY Acad Sci 2006; 1070: 276–81.
Fox EJ. Management of worsening multiple sclerosis with mitoxantrone: A review. Clin Ther 2006; 28: 461–74.
Frank B, Gupta S. A review of antioxidants and Alzheimer’s disease. Ann Clin Psychiatry 2005; 17: 269–86.
Gerdes JM, Katsanis N. Small molecule intervention in microtubule-associated human disease. Hum Mol Genet 2005; 14 Spec No. 2: R291–300.
Gray OM, et al. A systematic review of oral methotrexate for multiple sclerosis. Mult Scler 2006; 12: 507–10.
Griffin DE. Immune responses to RNA-virus infections of the CNS. Nat Rev Immunol 2003; 3: 493–502.
Hauser SL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676–88.
Henderson VW. Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience 2006; 138: 1031–9.
Huang HM, et al. Amyloid beta peptide impaired carbachol but not glutamate-mediated phosphoinositide pathways in cultured rat cortical neurons. Neurochem Res 2000; 25: 303–12.
Johnson KP, Panitch HS. Effects of experimental recombinant interferons on multiple sclerosis. Trans Am Clin Climatol Assoc 1988; 100: 171–6.
Johnson RT. Viral Infections of the Nervous System. 2nd edn (ed. Mark Placito EH). Philadelphia: Lippincott-Raven Publishers, 1998; 265–314.
Johnston JB, et al. HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 2001; 49: 230–41.
Kang BS, et al. Oral administration of live virus protects susceptible mice from developing Theiler’s virus-induced demyelinating disease. Virology 2007; 366: 185–96.
Kaur C, et al. Origin of microglia. Microsc Res Tech 2001; 54: 2–9.
Kelly M, et al. Modulating leukocyte recruitment in inflammation. J Allergy Clin Immunol 2007; 120: 3–10.
Kerfoot SM, Kubes P. Overlapping roles of P-selectin and alpha 4 integrin to recruit leukocytes to the central nervous system in experimental autoimmune encephalomyelitis. J Immunol 2002; 169: 1000–6.
Kilic E, et al. TAT-GDNF in neurodegeneration and ischemic stroke. CNS Drug Rev 2005; 11: 369–78.
Kosugi I, et al. Innate immune responses to cytomegalovirus infection in the developing mouse brain and their evasion by virus-infected neurons. Am J Pathol 2002; 161: 919–28.
Langer-Gould A, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353: 375–81.
Lapointe BM, et al. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004; 127: 2649–56.
Lee CZ, et al. Doxycycline suppresses cerebral matrix metalloproteinase-9 and angiogenesis induced by focal hyperstimulation of vascular endothelial growth factor in a mouse model. Stroke 2004; 35: 1715–9.
Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin 2007; 23: 2667–76.
Loewe R, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168: 4781–7.
Lovett-Racke AE, et al. Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 2004; 21: 719–31.
Lowenstein PR. Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective. Trends Immunol 2002; 23: 23–30.
Lucas SM, et al. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147 (Suppl 1): S232–40.
Maehlen J, et al. Axotomy induces MHC class I antigen expression on rat nerve cells. Neurosci Lett 1988; 92: 8–13.
Martinez-Rodriguez JE, et al. Cladribine in aggressive forms of multiple sclerosis. Eur J Neurol 2007; 14(6): 686–9.
Matney SE, Huff DR. Diagnosis and treatment of myasthenia gravis. Consult Pharm 2007; 22: 239–48.
Medyouf H, et al. Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia. Nat Med 2007; 13: 736–41.
Morrissey SP, et al. Mitoxantrone in the treatment of multiple sclerosis. Int MS J 2005; 12(3): 74–87.
Mueller BK, et al. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 2005; 4: 387–98.
Nash PT, Florin TH. Tumour necrosis factor inhibitors. Med J Aust 2005; 183: 205–8.
Neumann H. Control of glial immune function by neurons. Glia 2001; 36: 191–9.
Neumann H, et al. Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J Exp Med 1997; 185: 305–16.
O’Connor PW, et al. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006; 66: 894–900.
Orgogozo JM, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003; 61: 46–54.
Paintlia AS, et al. Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis. Am J Pathol 2006; 169: 1012–25.
Piraino PS, et al. Suppression of acute experimental allergic encephalomyelitis with a small molecule inhibitor of alpha4 integrin. Mult Scler 2005; 11: 683–90.
Polman C, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005; 64: 987–91.
Pozzi S, et al. Estrogen action in neuroprotection and brain inflammation. Ann NY Acad Sci 2006; 1089: 302–23.
Prinz M, et al. Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008; 28: 675–86.
Ransohoff RM, et al. Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 2003; 3: 569–81.
Reddy DS. Role of neurosteroids in catamenial epilepsy. Epilepsy Res 2004; 62: 99–118.
Reijerkerk A, et al. Diapedesis of monocytes is associated with MMP-mediated occludin disappearance in brain endothelial cells. FASEB J 2006; 20: 2550–2.
Ringshausen I, et al. The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells. Leukemia 2008; 22: 635–8.
Rogers J, et al. Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: Are microglia pathogenic in either disorder? Int Rev Neurobiol 2007; 82: 235–46.
Roney C, et al. Targeted nanoparticles for drug delivery through the blood–brain barrier for Alzheimer’s disease. J Control Release 2005; 108: 193–214.
Ropper AH. Selective treatment of multiple sclerosis. N Engl J Med 2006; 354: 965–7.
Ruffini F, et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001; 8: 1207–13.
Runstrom A, et al. Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-beta k.o. and wild type mice. J Neuroimmunol 2006; 173: 69–78.
Salama B, et al. Optic neuropathy in refractory neurosarcoidosis treated with TNF-alpha antagonist. Can J Ophthalmol 2006; 41: 766–8.
Schifitto G, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: A first report. Neurology 2006; 66: 919–21.
Schimrigk S, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13: 604–10.
Schwartz M, Kipnis J. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurol Sci 2005; 233: 163–6.
Scott LJ, Figgitt DP. Mitoxantrone: A review of its use in multiple sclerosis. CNS Drugs 2004; 18: 379–96.
Shytle RD, et al. Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004; 89: 337–43.
Steinman L. Elaborate interactions between the immune and nervous systems. Nature Immunol 2004; 5: 575–81.
Stepkowski SM. Molecular targets for existing and novel immunosuppressive drugs. Expert Rev Mol Med 2000; 2: 1–23.
Stuve O, et al. Statins as potential therapeutic agents in multiple sclerosis. Curr Neurol Neurosci Rep 2004; 4: 237–44.
Sugiyama K, et al. Comparison of suppressive potency between azathioprine and 6-mercaptopurine against mitogen-induced blastogenesis of human peripheral blood mononuclear cells in-vitro. J Pharm Pharmacol 2003; 55: 393–8.
Teixeira MM, et al. The role of lipocortin-1 in the inhibitory action of dexamethasone on eosinophil trafficking in cutaneous inflammatory reactions in the mouse. Br J Pharmacol 1998; 123: 538–44.
Thatcher GR, et al. NO chimeras as therapeutic agents in Alzheimer’s disease. Curr Alzheimer Res 2006; 3: 237–45.
Treumer F, et al. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121: 1383–8.
Uyttenhove C, Van Snick J. Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur J Immunol 2006; 36: 2868–74.
Wang C, et al. Antigen-specific therapy promotes repair of myelin and axonal damage in established EAE. J Neurochem 2006; 98: 1817–27.
Warren KG, et al. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006; 13: 887–95.
Waxman SG. Ions, energy and axonal injury: Towards a molecular neurology of multiple sclerosis. Trends Mol Med 2006; 12: 192–5.
Weber MS, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nature Med 2007; 13: 935–43.
Woodruff TM, et al. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J 2006; 20: 1407–17.
Xiu J, et al. Expression of nicotinic receptors on primary cultures of rat astrocytes and up-regulation of the alpha7, alpha4 and beta2 subunits in response to nanomolar concentrations of the beta-amyloid peptide(1–42). Neurochem Int 2005; 47: 281–90.
Yang JS, et al. Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-beta in Lewis rats. J Neuroimmunol 2004; 156: 3–9.
Yednock TA, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–6.
Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology 2002; 59: 802–8.
Yong VW, et al. Experimental models of neuroprotection relevant to multiple sclerosis. Neurology 2007; 68: pS32–7; discussion S43–54.
Yousry TA, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924–33.
Zheng YQ, et al. Effects of crocin on reperfusion-induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res 2007; 1138: 86.